Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AF150(S): a new functionally selective M1 agonist improves cognitive performance in rats

R Brandeis1, M Sapir, N Hafif

  • 1Israel Institute for Biological Research, Ness-Ziona.

Pharmacology, Biochemistry, and Behavior
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Frustrated and Concerned: Understanding Antipathy Towards Clients Who Engage in Nonsuicidal Self-Injury in Australian Mental Health Practitioners.

Clinical psychology & psychotherapy·2025
Same author

Developing a platform to investigate the heterogeneity of outcomes for patients with ovarian cancer.

BMJ open quality·2025
Same author

Controlling beam trajectory and transport in a tapered helical undulator.

Journal of synchrotron radiation·2025
Same author

The metabolic landscape of tetrahydrobiopterin metabolism disorders in the Republic of Ireland.

Molecular genetics and metabolism reports·2025
Same author

Analysis of substantiated welfare investigations in extensive farming systems in Victoria, Australia.

Australian veterinary journal·2024
Same author

Person-specific and pooled prediction models for binge eating, alcohol use and binge drinking in bulimia nervosa and alcohol use disorder.

Psychological medicine·2024
Same journal

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior·2026
Same journal

Modulation of prefrontal NMDA receptors reveals pharmacogenetic differences between SHR and SLA16 rat strains.

Pharmacology, biochemistry, and behavior·2026
Same journal

Spontaneous oxycodone withdrawal alters behavior and oligodendrocyte-related gene expression in mice.

Pharmacology, biochemistry, and behavior·2026
Same journal

Improvement in depressive symptoms in people undergoing cognitive behavioral therapy who supplemented with probiotics: An open-label, pilot study.

Pharmacology, biochemistry, and behavior·2026
Same journal

Long-term follow-up of children with autism spectrum disorder and severe treatment-resistant behavioral symptoms treated with purified cannabidiol.

Pharmacology, biochemistry, and behavior·2026
Same journal

Fluoxetine reduces anxiety-like behavior but increases motor impairments in the early stages of a progressive model of Parkinson's disease.

Pharmacology, biochemistry, and behavior·2026
See all related articles

AF150(S), a novel M1 agonist, effectively reversed cognitive deficits in a rat model. This compound shows promise for enhancing memory and cognition with a favorable safety profile.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cognitive Science

Background:

  • Cholinergic system dysfunction is implicated in cognitive impairments.
  • Developing selective M1 receptor agonists is a therapeutic strategy for cognitive disorders.

Purpose of the Study:

  • To evaluate the efficacy of AF150(S), a selective partial M1 agonist, in reversing cognitive deficits.
  • To assess the safety and pharmacodynamic profile of AF150(S).

Main Methods:

  • A rat model of memory deficits induced by AF64A administration.
  • Behavioral testing using step-through passive avoidance, Morris water maze, and radial arm maze tasks.
  • Evaluation of general toxicity and determination of the LD50.

Main Results:

Related Experiment Videos

  • AF150(S) significantly reversed performance impairments in all three behavioral tasks at low doses (0.5-5 mg/kg).
  • The safe dose of AF150(S) was greater than 40 mg/kg, with an LD50 greater than 500 mg/kg.
  • The compound demonstrated a favorable therapeutic index.

Conclusions:

  • AF150(S) exhibits potential cognitive-enhancing properties.
  • The mechanism may involve a specific enhancement of cholinergic function.
  • AF150(S) represents a promising candidate for treating cognitive impairments.